Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Bassarak, Nina ^a   Blankenstein, Thomas ^a   Brüning, Ansgar ^a   Dian, Darius ^a   Bergauer, Florian ^a   Friese, Klaus ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURGICAL TECHNIQUE; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; KAPLAN MEIER METHOD; LYMPH NODE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

AGED; CARCINOMA, ENDOMETRIOID; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952454056     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-224     Document Type: Article

References (25)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004, 54(1):8-29. 10.3322/canjclin.54.1.8, 14974761.
2. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8(6):541-552. 10.1634/theoncologist.8-6-541, 14657533.
3. FIGO stages (announcements). Gynecol Oncol 1989, 35:125-127.
4. Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W. Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynakol Geburtshilfliche Rundsch 2003, 43(2):104-110. 10.1159/000069163, 12649583.
5. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991, 40(1):55-65. 10.1016/0090-8258(91)90086-K, 1989916.
6. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987, 60(8 Suppl):2035-2041.
7. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F, Conner W. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995, 56(1):29-33. 10.1006/gyno.1995.1005, 7821843.
8. Orr JW, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary?. Am J Obstet Gynecol 1997, 176(4):777-788. discussion 788-779, 10.1016/S0002-9378(97)70601-X, 9125601.
9. Ceccaroni M, Savelli L, Bovicelli A, Alboni C, Ceccarini M, Farina A, Bovicelli L. Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anticancer Res 2004, 24(3b):2073-2078.
10. Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. Am J Obstet Gynecol 2008, 198(4):e451-455. discussion 457 e455-456.
11. Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006, 102(1):92-97. 10.1016/j.ygyno.2005.11.032, 16406063.
12. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005, 23(16):3668-3675. 10.1200/JCO.2005.04.144, 15738538.
13. Smith DC, Macdonald OK, Lee CM, Gaffney DK. Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer 2008, 18(2):255-261. 10.1111/j.1525-1438.2007.01020.x, 17624991.
14. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373(9658):125-136. 10.1016/S0140-6736(08)61766-3, 2646126, 19070889.
15. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004, 35(6):649-662. 10.1016/j.humpath.2004.02.007, 15188130.
16. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43(16):2434-2444. 10.1016/j.ejca.2007.08.014, 17911007.
17. Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K. Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 2009, 45(7):1304-1314. 10.1016/j.ejca.2009.01.008, 19231155.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
19. Cox DR. Regression models and life tables. J R Stat Soc B 1972, 34:187-220.
20. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S105-143. 10.1016/S0020-7292(06)60031-3, 17161155.
21. Dallenbach-Hellweg G. Histopathologie und Stadieneinteilung des Endometriumkarzinoms inklusive seiner Präkanzerosen. Onkologe 1999, 5:388-395.
22. Barakat RR, Lev G, Hummer AJ, Sonoda Y, Chi DS, Alektiar KM, Abu-Rustum NR. Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol 2007, 105(1):150-156. 10.1016/j.ygyno.2006.11.007, 17197012.
23. Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol 2001, 80(2):139-144. 10.1006/gyno.2000.6067, 11161851.
24. Gonzalez Bosquet J, Keeney GL, Mariani A, Webb MJ, Cliby WA. Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol 2003, 91(3):518-525. 10.1016/j.ygyno.2003.08.026, 14675670.
25. Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS. Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand 2008, 87(12):1361-1369. 10.1080/00016340802503054, 18951214.